Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Kwangrok Jung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2178-548X; OpenAlex author ID A5020979720. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 6 papers · 2026: 2 papers

Papers 18

  1. Digital SERS Nanoprobe Immunoassay With Single-Particle Sensing Resolution for Detection of Pancreatic Cancer Biomarkers From Clinical Blood Samples. Co-author DOI 10.1002/smtd.202600005↗
  2. Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations. Co-author DOI 10.1016/j.canlet.2025.218176↗
  3. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. Co-author DOI 10.1186/s12885-025-14124-w↗
  4. Spatial transcriptomics reveal high T cell and monocyte status as predictive and prognostic markers in pancreatic cancer. Co-author DOI 10.1186/s12967-025-06599-9↗
  5. Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. Co-author DOI 10.3389/fmicb.2025.1555479↗
  6. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. Co-author DOI 10.4251/wjgo.v17.i2.100167↗
  7. Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance. Co-author DOI 10.4251/wjgo.v17.i9.109055↗
  8. Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. Co-author DOI 10.5009/gnl240458↗
  9. Confined growth of Ag nanogap shells emitting stable Raman label signals for SERS liquid biopsy of pancreatic cancer. Co-author DOI 10.1016/j.bios.2023.115948↗
  10. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. Co-author DOI 10.1177/17588359241290482↗
  11. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Co-author DOI 10.5009/gnl230303↗
  12. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Co-author DOI 10.1177/17588359231175441↗
  13. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Co-author DOI 10.1038/s41598-022-24732-2↗
  14. Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Co-author DOI 10.21037/jgo-22-218↗
  15. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1050070↗
  16. Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13174454↗
  17. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. Co-author DOI 10.3390/jpm11020083↗
  18. Sex Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX Co-author DOI 10.21203/rs.3.rs-33720/v1↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 14 shared papers, 2020–2026 · strength 2.91
  2. Jaihwan Kim · 13 shared papers, 2020–2026 · strength 2.69
  3. Jong-Chan Lee · 11 shared papers, 2020–2026 · strength 2.24
  4. Jinwoo Ahn · 6 shared papers, 2022–2025 · strength 1.27
  5. Yuna Youn · 3 shared papers, 2025–2026 · strength 0.78
  6. Bo‐Mi Kim · 3 shared papers, 2023–2025 · strength 0.68
  7. Jae Hyup Jung · 4 shared papers, 2021–2024 · strength 0.66
  8. Jin Won Kim · 4 shared papers, 2020–2024 · strength 0.64
  9. Jae Hyeong Kim · 2 shared papers, 2025–2026 · strength 0.57
  10. Yoo‐Seok Yoon · 3 shared papers, 2021–2025 · strength 0.55
  11. Ho‐Seong Han · 3 shared papers, 2021–2025 · strength 0.55
  12. In‐Jun Hwang · 2 shared papers, 2024–2026 · strength 0.50
  13. Chanhee Choi · 2 shared papers, 2024–2026 · strength 0.50
  14. Jong‐Ho Kim · 2 shared papers, 2024–2026 · strength 0.50
  15. Jun Suh Lee · 2 shared papers, 2021–2024 · strength 0.33
  16. Jinkook Kim · 2 shared papers, 2020–2021 · strength 0.26
  17. Kyoung Un Park · 1 shared paper, 2025 · strength 0.23
  18. Soomin Ahn · 1 shared paper, 2025 · strength 0.22
  19. Yeon Bi Han · 1 shared paper, 2025 · strength 0.22
  20. In Rae Cho · 1 shared paper, 2024 · strength 0.20
  21. Do‐Youn Oh · 1 shared paper, 2024 · strength 0.20
  22. Sang Hyub Lee · 1 shared paper, 2024 · strength 0.20
  23. Jin Ho Choi · 1 shared paper, 2024 · strength 0.20
  24. Min Kyu Kim · 1 shared paper, 2024 · strength 0.20
  25. Dong‐Won Ahn · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.